BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

...compared with placebo plus azacitidine. Venclexta has accelerated approval from FDA in combination with azacitidine, decitabine...
BioCentury | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

...and Tomudex raltitrexed from AstraZeneca plc (LSE:AZN; NYSE:AZN); Xeloda capecitabine from Roche (SIX:ROG; OTCQX:RHHBY); Dacogen decitabine...
BioCentury | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

...combination of cedazuridine and decitabine met the primary endpoint of decitabine exposure equivalence with IV decitabine...
BioCentury | Apr 19, 2019
Product Development

Companies poised to take Chinese checkpoints global

...Astex Pharmaceuticals Inc. and involved in global launches of drugs including myelodysplastic syndrome therapy Dacogen decitabine...
BioCentury | Nov 30, 2018
Clinical News

FDA approves two drugs for first-line AML

...AbbVie Inc. (NYSE:ABBV) and Genentech Inc. for use in combination with low-dose cytarabine, azacitidine or decitabine...
...For AML, FDA recommends 400 mg Venclexta daily when used in combination with azacitidine or decitabine...
BioCentury | Nov 21, 2018
Company News

FDA approves two drugs for first-line AML

...AbbVie Inc. (NYSE:ABBV) and Genentech Inc. for use in combination with low-dose cytarabine, azacitidine or decitabine...
...For AML, FDA recommends 400 mg Venclexta daily when used in combination with azacitidine or decitabine...
BioCentury | Aug 3, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

...trial to treat myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) after failure of azacitidine, decitabine...
...significantly improve complete response rate and overall survival (OS) compared with physician’s choice of azacitidine, decitabine...
...is the second-generation version of the generic drug decitabine, which Astex launched in 2006 as Dacogen...
BioCentury | Jul 31, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

...trial to treat myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) after failure of azacitidine, decitabine...
...significantly improve complete response rate and overall survival (OS) compared with physician’s choice of azacitidine, decitabine...
...is the second-generation version of the generic drug decitabine, which Astex launched in 2006 as Dacogen...
BioCentury | Apr 13, 2018
Company News

Novo Nordisk licenses sickle cell candidate from EpiDestiny

...oncology indications. EPI01 is an oral formulation of two small molecules -- DNA methyltransferase inhibitor decitabine...
BioCentury | Apr 5, 2018
Company News

Novo in deal for EpiDestiny's hematology candidate

...oncology indications. EPI01 is an oral formulation of two small molecules -- DNA methyltransferase inhibitor decitabine...
Items per page:
1 - 10 of 294